pharma · high blood pressure · increased blood clotting
APREMEDA s.r.o
s.r.o.
s.r.o is a pharma organization headquartered in EU. Primary therapeutic focus areas include high blood pressure, increased blood clotting, Stable Ischemic Heart Disease. NovaPharmaNews links 5 clinical program(s), 0 drug
Company details
- Status
- Public
- HQ
- EU
- Founded
- 2020
- Employees
- 18
- Programs
- 5
- Drugs
- 16
- Patents
- 0
A pilot for UDCA causes a reduction in chol…
Phase 1 · other · UDCA causes a reduction in cholesterol saturation of the bile by inhibiting cholesterol absorption in the intestine and reducing cholesterol secretion into the bile. Presumably, cholesterol gallstones are gradually dissolved by dispersion of the cholesterol and formation of liquid crystals.
A pilot for UDCA causes a reduction in chol… for UDCA causes a reduction in cholesterol saturation of the bile by inhibiting cholesterol absorption in the intestine and reducing cholesterol secretion into the bile. Presumably, cholesterol gallstones are gradually dissolved by dispersion of the cholesterol and formation of liquid crystals. is a Phase 1 program (other) at s.r.o. with 1 ClinicalTrials.gov record(s).
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- s.r.o.
- Phase
- Phase 1
- Modality
- other
- Indication
- UDCA causes a reduction in cholesterol saturation of the bile by inhibiting cholesterol absorption in the intestine and reducing cholesterol secretion into the bile. Presumably, cholesterol gallstones are gradually dissolved by dispersion of the cholesterol and formation of liquid crystals.
- Status
- active
- Trials
- 1